Skip to main content
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 May;115(2):373–379. doi: 10.1111/j.1476-5381.1995.tb15888.x

Effects of endothelin receptor antagonism with bosentan on peripheral nerve function in experimental diabetes.

E J Stevens 1, D R Tomlinson 1
PMCID: PMC1908327  PMID: 7670740

Abstract

1. The effects of the non-selective endothelin (ET) receptor (ETA/ETB) antagonist, bosentan, on sciatic nerve dysfunction in experimental diabetes were investigated. 2. Rats with 5-6 weeks untreated streptozotocin-diabetes exhibited characteristic slowed motor nerve conduction velocity (mean +/- s.d., 36.6 +/- 3.4 m s-1) and nerve laser Doppler flux (197 +/- 64 arbitrary units) compared to age-matched control animals (42.7 +/- 2.4 m s-1 and 398 +/- 77 arbitrary units, respectively). Preventative treatment of diabetic rats with bosentan at 100 mg kg-1 day-1 p.o. attenuated both these deficits (39.7 +/- 3.0 m s-1 and 305 +/- 56 arbitrary units, respectively) without affecting mean arterial pressure. 3. In control and untreated diabetic rats, ET-1, 1 nmol kg-1 i.v., caused an initial hypotension (duration, 30 +/- 13 and 26 +/- 9 s, respectively; change in mean arterial pressure, -27 +/- 13 and -25 +/- 7 mmHg, respectively) followed by prolonged hypertension (change in mean arterial pressure, 52 +/- 18 and 31 +/- 5 mmHg, respectively). Effectiveness of the chronic bosentan treatment was demonstrated by inhibition of the hypotensive response to ET-1 in treated diabetic rats (duration, 5 +/- 2 s; change in mean arterial pressure, -4 +/- 2 mmHg) although the hypertension was unaltered (change in mean arterial pressure, 32 +/- 9 mmHg). 4. Acute i.v. administration of 10 mg kg-1 bosentan caused variable and transient rises in nerve laser Doppler flux in control (78 +/- 63 arbitrary units) and untreated diabetic rats (93 +/- 77 arbitrary units).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
373

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertello P., Veglio F., Pinna G., Gurioli L., Molino P., Alban S., Chiandussi L. Plasma endothelin in NIDDM patients with and without complications. Diabetes Care. 1994 Jun;17(6):574–577. doi: 10.2337/diacare.17.6.574. [DOI] [PubMed] [Google Scholar]
  2. Bigaud M., Pelton J. T. Discrimination between ETA- and ETB-receptor-mediated effects of endothelin-1 and [Ala1,3,11,15]endothelin-1 by BQ-123 in the anaesthetized rat. Br J Pharmacol. 1992 Dec;107(4):912–918. doi: 10.1111/j.1476-5381.1992.tb13385.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cameron N. E., Cotter M. A., Archibald V., Dines K. C., Maxfield E. K. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia. 1994 May;37(5):449–459. doi: 10.1007/s001250050131. [DOI] [PubMed] [Google Scholar]
  4. Cameron N. E., Cotter M. A., Dines K. C., Maxfield E. K., Carey F., Mirrlees D. J. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism. Diabetologia. 1994 Jul;37(7):651–663. doi: 10.1007/BF00417688. [DOI] [PubMed] [Google Scholar]
  5. Cameron N. E., Cotter M. A., Low P. A. Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am J Physiol. 1991 Jul;261(1 Pt 1):E1–E8. doi: 10.1152/ajpendo.1991.261.1.E1. [DOI] [PubMed] [Google Scholar]
  6. Cotter M. A., Dines K. C., Cameron N. E. Prevention and reversal of motor and sensory peripheral nerve conduction abnormalities in streptozotocin-diabetic rats by the prostacyclin analogue iloprost. Naunyn Schmiedebergs Arch Pharmacol. 1993 May;347(5):534–540. doi: 10.1007/BF00166747. [DOI] [PubMed] [Google Scholar]
  7. ELIASSON S. G. NERVE CONDUCTION CHANGES IN EXPERIMENTAL DIABETES. J Clin Invest. 1964 Dec;43:2353–2358. doi: 10.1172/JCI105109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fukui M., Nakamura T., Ebihara I., Osada S., Tomino Y., Masaki T., Goto K., Furuichi Y., Koide H. Gene expression for endothelins and their receptors in glomeruli of diabetic rats. J Lab Clin Med. 1993 Aug;122(2):149–156. [PubMed] [Google Scholar]
  9. Gardiner S. M., Kemp P. A., March J. E., Bennett T. Effects of bosentan (Ro 47-0203), an ETA-, ETB-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats. Br J Pharmacol. 1994 Jul;112(3):823–830. doi: 10.1111/j.1476-5381.1994.tb13153.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gregersen G. Diabetic neuropathy: influence of age, sex, metabolic control, and duration of diabetes on motor conduction velocity. Neurology. 1967 Oct;17(10):972–980. doi: 10.1212/wnl.17.10.972. [DOI] [PubMed] [Google Scholar]
  11. Gruden G., Cavallo-Perin P., Bazzan M., Stella S., Vuolo A., Pagano G. PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria. Diabetes. 1994 Mar;43(3):426–429. doi: 10.2337/diab.43.3.426. [DOI] [PubMed] [Google Scholar]
  12. Hotta N., Kakuta H., Fukasawa H., Koh N., Sakakibara F., Komori H., Sakamoto N. Effect of niceritrol on streptozocin-induced diabetic neuropathy in rats. Diabetes. 1992 May;41(5):587–591. doi: 10.2337/diab.41.5.587. [DOI] [PubMed] [Google Scholar]
  13. Kappelle A. C., Biessels G. J., Van Buren T., Erkelens D. W., De Wildt D. J., Gispen W. H. Effects of nimodipine on sciatic nerve blood flow and vasa nervorum responsiveness in the diabetic rat. Eur J Pharmacol. 1993 Nov 30;250(1):43–49. doi: 10.1016/0014-2999(93)90619-s. [DOI] [PubMed] [Google Scholar]
  14. Kiff R. J., Gardiner S. M., Compton A. M., Bennett T. Selective impairment of hindquarters vasodilator responses to bradykinin in conscious Wistar rats with streptozotocin-induced diabetes mellitus. Br J Pharmacol. 1991 Jun;103(2):1357–1362. doi: 10.1111/j.1476-5381.1991.tb09793.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kiff R. J., Gardiner S. M., Compton A. M., Bennett T. The effects of endothelin-1 and NG-nitro-L-arginine methyl ester on regional haemodynamics in conscious rats with streptozotocin-induced diabetes mellitus. Br J Pharmacol. 1991 Jun;103(2):1321–1326. doi: 10.1111/j.1476-5381.1991.tb09787.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Komuro I., Kurihara H., Sugiyama T., Yoshizumi M., Takaku F., Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett. 1988 Oct 10;238(2):249–252. doi: 10.1016/0014-5793(88)80489-7. [DOI] [PubMed] [Google Scholar]
  17. Low P. A., Tuck R. R. Effects of changes of blood pressure, respiratory acidosis and hypoxia on blood flow in the sciatic nerve of the rat. J Physiol. 1984 Feb;347:513–524. doi: 10.1113/jphysiol.1984.sp015079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Maxfield E. K., Cameron N. E., Cotter M. A., Dines K. C. Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats and nerve function. Diabetologia. 1993 Dec;36(12):1230–1237. doi: 10.1007/BF00400799. [DOI] [PubMed] [Google Scholar]
  19. Mayer J. H., Tomlinson D. R. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats. Diabetologia. 1983 Nov;25(5):433–438. doi: 10.1007/BF00282524. [DOI] [PubMed] [Google Scholar]
  20. Monafo W. W., Eliasson S. G., Shimazaki S., Sugimoto H. Regional blood flow in resting and stimulated sciatic nerve of diabetic rats. Exp Neurol. 1988 Mar;99(3):607–614. doi: 10.1016/0014-4886(88)90177-x. [DOI] [PubMed] [Google Scholar]
  21. Morabito E., Corsico N., Serafini S., Martelli E. A. Elevated urinary excretion of endothelins in streptozotocin diabetic rats. Life Sci. 1994;54(11):PL197–PL200. doi: 10.1016/0024-3205(94)90168-6. [DOI] [PubMed] [Google Scholar]
  22. Newrick P. G., Wilson A. J., Jakubowski J., Boulton A. J., Ward J. D. Sural nerve oxygen tension in diabetes. Br Med J (Clin Res Ed) 1986 Oct 25;293(6554):1053–1054. doi: 10.1136/bmj.293.6554.1053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ohno A., Kanazawa A., Tanaka A., Miwa T., Ito H. Effect of a prostaglandin I2 derivative (iloprost) on peripheral neuropathy of diabetic rats. Diabetes Res Clin Pract. 1992 Nov;18(2):123–130. doi: 10.1016/0168-8227(92)90008-f. [DOI] [PubMed] [Google Scholar]
  24. Patiño R., Ibarra J., Molino A., Fernandez-Durango R., Moya J., Fernandez-Cruz A. Increased plasma endothelin in diabetes: an atherosclerosis marker? Diabetologia. 1994 Mar;37(3):333–334. doi: 10.1007/BF00398065. [DOI] [PubMed] [Google Scholar]
  25. Predel H. G., Meyer-Lehnert H., Bäcker A., Stelkens H., Kramer H. J. Plasma concentrations of endothelin in patients with abnormal vascular reactivity. Effects of ergometric exercise and acute saline loading. Life Sci. 1990;47(20):1837–1843. doi: 10.1016/0024-3205(90)90286-z. [DOI] [PubMed] [Google Scholar]
  26. Shindo H., Tawata M., Aida K., Onaya T. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy. J Clin Endocrinol Metab. 1992 Feb;74(2):393–398. doi: 10.1210/jcem.74.2.1370506. [DOI] [PubMed] [Google Scholar]
  27. Stevens E. J., Carrington A. L., Tomlinson D. R. Nerve ischaemia in diabetic rats: time-course of development, effect of insulin treatment plus comparison of streptozotocin and BB models. Diabetologia. 1994 Jan;37(1):43–48. doi: 10.1007/BF00428776. [DOI] [PubMed] [Google Scholar]
  28. Stevens E. J., Carrington A. L., Tomlinson D. R. Prostacyclin release in experimental diabetes: effects of evening primrose oil. Prostaglandins Leukot Essent Fatty Acids. 1993 Sep;49(3):699–706. doi: 10.1016/0952-3278(93)90081-7. [DOI] [PubMed] [Google Scholar]
  29. Stevens E. J., Lockett M. J., Carrington A. L., Tomlinson D. R. Essential fatty acid treatment prevents nerve ischaemia and associated conduction anomalies in rats with experimental diabetes mellitus. Diabetologia. 1993 May;36(5):397–401. doi: 10.1007/BF00402274. [DOI] [PubMed] [Google Scholar]
  30. Takahashi K., Ghatei M. A., Lam H. C., O'Halloran D. J., Bloom S. R. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia. 1990 May;33(5):306–310. doi: 10.1007/BF00403325. [DOI] [PubMed] [Google Scholar]
  31. Takahashi K., Suda K., Lam H. C., Ghatei M. A., Bloom S. R. Endothelin-like immunoreactivity in rat models of diabetes mellitus. J Endocrinol. 1991 Jul;130(1):123–127. doi: 10.1677/joe.0.1300123. [DOI] [PubMed] [Google Scholar]
  32. Takeda Y., Miyamori I., Yoneda T., Takeda R. Production of endothelin-1 from the mesenteric arteries of streptozotocin-induced diabetic rats. Life Sci. 1991;48(26):2553–2556. doi: 10.1016/0024-3205(91)90611-e. [DOI] [PubMed] [Google Scholar]
  33. Tsunoda K., Abe K., Sato T., Yokosawa S., Yoshinaga K. Decreased conversion of big endothelin-1 to endothelin-1 in patients with diabetes mellitus. Clin Exp Pharmacol Physiol. 1991 Oct;18(10):731–732. doi: 10.1111/j.1440-1681.1991.tb01388.x. [DOI] [PubMed] [Google Scholar]
  34. Tuck R. R., Schmelzer J. D., Low P. A. Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain. 1984 Sep;107(Pt 3):935–950. doi: 10.1093/brain/107.3.935. [DOI] [PubMed] [Google Scholar]
  35. Vongsavan N., Matthews B. Some aspects of the use of laser Doppler flow meters for recording tissue blood flow. Exp Physiol. 1993 Jan;78(1):1–14. doi: 10.1113/expphysiol.1993.sp003664. [DOI] [PubMed] [Google Scholar]
  36. Ward K. K., Low P. A., Schmelzer J. D., Zochodne D. W. Prostacyclin and noradrenaline in peripheral nerve of chronic experimental diabetes in rats. Brain. 1989 Feb;112(Pt 1):197–208. doi: 10.1093/brain/112.1.197. [DOI] [PubMed] [Google Scholar]
  37. Warner T. D., Allcock G. H., Corder R., Vane J. R. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. Br J Pharmacol. 1993 Oct;110(2):777–782. doi: 10.1111/j.1476-5381.1993.tb13879.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Webb M. L., Dickinson K. E., Delaney C. L., Liu E. C., Serafino R., Cohen R. B., Monshizadegan H., Moreland S. The endothelin receptor antagonist, BQ-123, inhibits angiotensin II-induced contractions in rabbit aorta. Biochem Biophys Res Commun. 1992 Jun 30;185(3):887–892. doi: 10.1016/0006-291x(92)91710-8. [DOI] [PubMed] [Google Scholar]
  39. Whittle B. J., Lopez-Belmonte J., Rees D. D. Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P and endothelin in the rat by a specific inhibitor of nitric oxide formation. Br J Pharmacol. 1989 Oct;98(2):646–652. doi: 10.1111/j.1476-5381.1989.tb12639.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Yasuda H., Sonobe M., Yamashita M., Terada M., Hatanaka I., Huitian Z., Shigeta Y. Effect of prostaglandin E1 analogue TFC 612 on diabetic neuropathy in streptozocin-induced diabetic rats. Comparison with aldose reductase inhibitor ONO 2235. Diabetes. 1989 Jul;38(7):832–838. doi: 10.2337/diab.38.7.832. [DOI] [PubMed] [Google Scholar]
  41. Zochodne D. W., Ho L. T., Gross P. M. Acute endoneurial ischemia induced by epineurial endothelin in the rat sciatic nerve. Am J Physiol. 1992 Dec;263(6 Pt 2):H1806–H1810. doi: 10.1152/ajpheart.1992.263.6.H1806. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES